DuPont eschews a spin-out By Kathryn Calkins
Staff writer

DuPont's plans to create a tracking stock for its life sciences businesses is in line with moves the company began last year to hive off the group from its slower-growing chemicals and other businesses. But skeptics may question whether DuPont is moving too late to create a competitive life sciences play, and whether last week's tracking stock announcement simply sets the stage for an acquisition by its much larger competitors - or for a complete uncoupling of life sciences from the rest of the company.

Last May, as part of a new life sciences focus for the company, DuPont decided to consolidate its three life science-related businesses - agricultural enterprises, pharmaceuticals and central R&D - into one group. At the time, the company said its goal would be to obtain 30 percent of its earnings from life sciences within three years (
see BioCentury, May 18, 1998